Mergers & acquisitions
With the acquisition of Dublin-based Shire by Japan-based Takeda Pharmaceutical pretty much a done-deal, Takeda appears to be getting its financial house in order before it closes.
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
The third time is the charm for AstraZeneca and its hyperkalemia treatment that has been dogged by manufacturing issues. After multiple rejections, the U.S. Food and Drug Administration finally gave its approval for the treatment.
Only days after Eli Lilly and Company agreed to pay $1.6 billion for ARMO BioSciences, the Indianapolis-based drug company is acquiring AurKa Pharma, an oncology company.
The ink is still drying on the contracts for Japan’s Takeda Pharmaceutical’s acquisition of Dublin-based Shire for about $62.2 billion, but company executives are sharing some of the “inside baseball” about what went on behind the scenes of the deal.
Earlier this week Amneal Pharmaceuticals and Impax Laboratories completed their business merger, forming the new Amneal Pharmaceuticals. The combined companies are now the fifth largest generics business in the United States.
Shares of Armo BioSciences have soared more than 67 percent in premarket trading after Eli Lilly announced it had struck a deal to acquire the company for $1.6 billion in an all cash deal.
Novartis’ generics division, Sandoz, has been struggling in the face of intense pricing pressure. As a result, Novartis has been looking to sell off some of its Sandoz businesses.
Dublin-based Shire agreed to be acquired by Japan-based Takeda Pharmaceutical, with both boards approving the deal.
Celgene is eying the first quarter of 2019 to submit a second New Drug Application (NDA) for multiple sclerosis treatment ozanimod.
PRESS RELEASES